New Sickle Cell Therapies Will Be Out of Reach Where They Are Needed Most
Nasra Gwoto, 10, and her brother, Ramadhani, 12, traveled with their mother from Tanzania to India to get a bone-marrow transplant for sickle cell disease. The procedure is risky, and their mother wishes they could have received a new gene therapy instead. There is no clear path for African…#nasragwoto #tanzania #african #lyfgenia #bluebirdbio #vertex #saudiarabia #africa #whatsapp #shanimgaraganza (Source: Reuters: Health)
Source: Reuters: Health - December 9, 2023 Category: Consumer Health News Source Type: news
Crispr Whipsaws Lower After FDA OKs Gene-Editing Treatment
Shares of Crispr Therapeutics (CRSP) had a volatile day on Friday after the Food and Drug Administration approved the company's groundbreaking gene-editing treatment for sickle cell disease. CRSP stock rallied ahead of the news, but shares then fell sharply shedding more than 8%. The FDA approved…#crisprtherapeutics #crsp #fda #nicoleverdun #healthcare #regulatoryagency #vrtx #crisprsurgesafter (Source: Reuters: Health)
Source: Reuters: Health - December 8, 2023 Category: Consumer Health News Source Type: news
Gene editing is now a medical reality
The U.S. Food and Drug Administration on Friday approved the first gene editing treatment, a breakthrough in medical technology that paves a new path for treating hundreds of diseases. The new therapy treats sickle cell anemia by using CRISPR – a bacterial immunological response tool – to switch…#sarahzhang #atlantic #crispr #google #deepvariant (Source: Reuters: Health)
Source: Reuters: Health - December 8, 2023 Category: Consumer Health News Source Type: news
New Sickle Cell Therapies Will Be Out of Reach Where They Are Needed Most
There is no clear path for African patients to get access to the treatments, which have multimillion-dollar price tags and are highly complex to manufacture and deliver. (Source: NYT Health)
Source: NYT Health - December 8, 2023 Category: Consumer Health News Authors: Rebecca Robbins and Stephanie Nolen Tags: Sickle Cell Anemia Genetic Engineering Blood Genetics and Heredity Income Inequality Bone Marrow Drugs (Pharmaceuticals) Therapy and Rehabilitation Developing Countries Crispr (DNA) Transplants Stem Cells Food and Drug Administrati Source Type: news
FDA approves world-first gene editing treatment: Sickle cell therapy gives hope to 100,000 Americans with incurable disease - but it'll cost millions of dollars per DOSE
The US FDA approved the first gene editing therapy to treat patients with sickle cell disease - a crippling condition that leaves sufferers in life-altering pain. (Source: the Mail online | Health)
Source: the Mail online | Health - December 8, 2023 Category: Consumer Health News Source Type: news
FDA approves 2 gene therapies for sickle cell. One is the first to use the editing tool CRISPR
U.S. regulators have approved two gene therapies for sickle cell disease (Source: ABC News: Health)
Source: ABC News: Health - December 8, 2023 Category: Consumer Health News Tags: Health Source Type: news
FDA Approves Lyfgenia (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
SOMERVILLE, Mass.--(BUSINESS WIRE)--Dec. 8, 2023-- bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird bio” or“bluebird”) today announced the U.S. Food and Drug Administration (FDA) has approved Lyfgenia (pronounced as... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 8, 2023 Category: Drugs & Pharmacology Source Type: news
First Gene-Editing Therapies for Sickle Cell Disease Approved by FDA
FRIDAY, Dec. 8, 2023 -- Two milestone gene therapies for sickle cell disease have been approved by the U.S. Food and Drug Administration.Casgevy is the first medicine available in the United States to treat a genetic disease using the CRISPR... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 8, 2023 Category: Pharmaceuticals Source Type: news
First Gene-Editing Therapies for Sickle Cell Disease, Casgevy and Lyfgenia, Approved by FDA
FRIDAY, Dec. 8, 2023 -- Two milestone gene therapies for sickle cell disease have been approved by the U.S. Food and Drug Administration.
Casgevy is the first medicine available in the United States to treat a genetic disease using the CRISPR... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 8, 2023 Category: Pharmaceuticals Source Type: news
FDA approves first human gene editing therapy for sickle cell disease
The Food and Drug Administration Friday approved a new sickle cell disease treatment using the CRISPR genome editing technology. It ' s the first approved human gene editing therapy. (Source: Health News - UPI.com)
Source: Health News - UPI.com - December 8, 2023 Category: Consumer Health News Source Type: news
Here's how much Vertex, bluebird's new sickle-cell gene therapies will cost
The new sickle-cell disease drugs made by three Boston-area companies come with multimillion-dollar price tags. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 8, 2023 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news
First CRISPR Sickle Cell Patient ‘Reborn’: FDA Approves Treatment
The FDA's approval of Casgevy, which uses the Nobel Prize-winning gene-editing therapy to treat patients with sicke cell disease, opens the door to many other therapies. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 8, 2023 Category: Pharmaceuticals Authors: Ellen Matloff, Contributor Tags: Healthcare /healthcare Innovation /innovation Editors' Pick editors-pick business pharma & standard Source Type: news
US FDA approves two gene therapies for sickle cell disease
The US Food and Drug Administration (FDA) has approved two gene therapies for sickle cell disease, including the first treatment in the US based on CRISPR gene editing technology. Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, and bluebird bio's Lyfgenia were approved for people aged 12 years and older. (Source: The Economic Times)
Source: The Economic Times - December 8, 2023 Category: Consumer Health News Source Type: news
FDA OKs Two Gene-Editing Therapies for Sickle Cell Disease FDA OKs Two Gene-Editing Therapies for Sickle Cell Disease
The approval for the two gene-editing treatments, called exa-cel and lovo-cel, could help thousands with the blood disorder.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 8, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
US regulators approve two gene therapies for sickle cell disease
Blood disorder that can lead to premature death affects estimated 100,000 people in the United States, most of whom are BlackThe US Food and Drug Administration has approved a pair of gene therapies for sickle cell disease, including the first treatment based on the breakthrough Crispr gene-editing technology, opening up two “transformative therapy” avenues for some patients.The FDA approved Lyfgenia from Bluebird Bio, and a separate treatment called Casgevy by partners Vertex Pharmaceuticals and Crispr Therapeutics. Both therapies are made from the patients ’ own blood stem cells and were approved for people aged 12...
Source: Guardian Unlimited Science - December 8, 2023 Category: Science Authors: Edward Helmore and agencies Tags: US news Health World news Society Medicine Gene editing Science Source Type: news
